checkAd

     358  0 Kommentare Galapagos initiates Phase 1 study with novel CF corrector GLPG3221 - Seite 3


    ¹Orkambi® is a marketed product of Vertex Pharmaceuticals




    Lesen Sie auch

    This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Galapagos NV via Globenewswire

    Aktuelle Themen


    GlobeNewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren
    Seite 3 von 3

    Verfasst von GlobeNewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Galapagos initiates Phase 1 study with novel CF corrector GLPG3221 - Seite 3 Triggers a $10 million milestone payment from AbbVieSixth clinical candidate in cystic fibrosis portfolio Mechelen, Belgium; 21 November 2017; 22.01 CET -Galapagos NV (Euronext & NASDAQ: GLPG) announces initiation of a Phase 1 study with a novel …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer